What is the current Inhaler Medicine market size?

The current Inhaler Medicine market size is approximately USD 32.6 billion as of 2023.

What is the growth forecast for the Inhaler Medicine market?

The market is expected to grow at a CAGR of 6.8% from 2023 to 2028.

What are the key drivers of the Inhaler Medicine market?

Rising respiratory disease prevalence and increasing demand for inhaler devices drive the market.

What are the challenges faced by the Inhaler Medicine market?

Stringent regulatory requirements and high development costs pose significant challenges.

Which regions are the leaders in the Inhaler Medicine market?

North America and Europe are the leading regions due to high disease prevalence.

Who are the top companies in the Inhaler Medicine market?

GlaxoSmithKline, AstraZeneca, and Boehringer Ingelheim are among the top market players.

What are the future opportunities in the Inhaler Medicine market?

Increasing demand for smart inhalers and growing emerging markets present opportunities.

How does technology impact the Inhaler Medicine market?

Advances in digital inhalers and connected devices improve patient outcomes and adherence.

What is the regulatory landscape for the Inhaler Medicine market?

Regulatory bodies like FDA and EMA ensure strict safety and efficacy standards.

What is the future outlook for the Inhaler Medicine market?

The market is expected to witness significant growth due to increasing respiratory disease prevalence.

Inhaler Medicine Size, Share & Forecast Analysis 2025–2033

Inhaler Medicine by Application (COPD, Asthma, Other), by Types (Short-acting Medicines, Long-acting Medicines), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $8.5 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $8.5 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Inhaler Medicine Market Size | CAGR 7.2 Forecast 2033

Inhaler Medicine Size, Share & Forecast Analysis 2025–2033

🏭 Healthcare🌍 Global

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $8.5 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $8.5 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Inhaler Medicine Market Overview

The Inhaler Medicine market refers to the industry that produces and distributes inhalation therapies for respiratory diseases. As a crucial sector in the healthcare industry, the Inhaler Medicine market size is anticipated to reach $43.8 billion by 2026. The growth outlook for this market is promising, with a market forecast indicating a compound annual growth rate (CAGR) of 5.5% during the forecast period. The industry expansion is driven by increasing prevalence of respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and advancements in inhaler technologies. The market scope encompasses various types of inhalers, including metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers, catering to diverse patient needs and preferences.

Loading chart…

The growth forecast for the Inhaler Medicine market is influenced by several key forces, including technology shifts towards more efficient and user-friendly inhaler designs, regulations promoting the development of generic and biosimilar inhalation therapies, and consumer behavior favoring preventative care and self-management of respiratory conditions. The largest region in the Inhaler Medicine market is North America, while the fastest-growing region is expected to be Asia-Pacific, driven by increasing healthcare expenditure and rising awareness of respiratory diseases. As the market continues to evolve, industry players must navigate these dynamics to capitalize on emerging opportunities and maintain a competitive edge.

Report Overview

Report Attribute	Details
Market size value in 2025	8.50 million
Revenue forecast in 2033	14.82 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	GSK; AstraZeneca; Chiesi; Boehringer Ingelheim; Novartis; Teva; Organon
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Inhaler Medicine market is poised for significant growth, driven by a combination of factors that are reshaping the industry landscape. As the global population grapples with rising instances of respiratory diseases, the demand for effective inhaler medicines is on the rise, subsequently influencing the Inhaler Medicine market size and growth forecast.

Growth Drivers2 items

Advancements in inhaler technology are leading to the development of more efficient and user-friendly devices, which is driving adoption rates and fueling market expansion. This is particularly evident in the increasing preference for dry powder inhalers over traditional metered-dose inhalers.

Government initiatives and awareness campaigns aimed at promoting respiratory health are contributing to the growth of the Inhaler Medicine market, as more individuals seek medical intervention for respiratory conditions, thereby boosting the demand for inhaler medicines.

Restraints2 items

Stringent regulatory requirements governing the approval and marketing of inhaler medicines can hinder the entry of new players into the market, potentially limiting the Inhaler Medicine market size. This is because compliance with these regulations can be both time-consuming and costly.

The high development costs associated with creating innovative inhaler devices and medicines can deter investment, acting as a restraint on the overall growth of the Inhaler Medicine market and impacting its growth forecast.

Opportunities2 items

The increasing prevalence of chronic respiratory diseases in emerging economies presents significant opportunities for manufacturers of inhaler medicines to expand their market reach. By targeting these regions, companies can capitalize on unmet medical needs and contribute to the growth of the Inhaler Medicine market.

The integration of digital technologies into inhaler devices, such as sensors and mobile apps, offers opportunities for the development of more personalized and effective treatment options, which can drive innovation and growth in the Inhaler Medicine market.

Challenges2 items

The Inhaler Medicine market faces challenges related to environmental sustainability, particularly concerning the propellants used in inhalers, which contribute to greenhouse gas emissions. Addressing these concerns through the development of more eco-friendly alternatives is crucial.

Ensuring access to inhaler medicines in low- and middle-income countries remains a significant challenge due to factors such as high costs, lack of infrastructure, and limited healthcare resources, affecting the overall growth forecast of the Inhaler Medicine market.

Market Segmentation

Loading chart…

The Inhaler Medicine market can be segmented based on Application, which refers to the specific use case or therapeutic area where inhalers are utilized. This segmentation category contributes to the overall Inhaler Medicine market size by highlighting the varying demand for inhalers across different medical conditions, such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. Understanding the application-based segmentation is crucial for market players to tailor their products and marketing strategies to meet the unique needs of each therapeutic area, ultimately driving growth in the Inhaler Medicine segmentation.

Another significant segmentation category in the Inhaler Medicine market is Types, which encompasses various subtypes of inhalers, including metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers. Each subtype has its own set of characteristics, advantages, and limitations, influencing patient preferences, prescription rates, and ultimately, market share. By analyzing the types of inhalers, manufacturers can identify opportunities to innovate and improve existing products, addressing the specific needs of healthcare providers and patients, and expanding their presence in the market taxonomy.

Inhaler Medicine Segmentation Breakdown7 items

Application

COPD

Asthma

Other

Types

Short-acting Medicines

Long-acting Medicines

Regional Insights

Loading chart…

The Inhaler Medicine market growth is expected to vary across regions, with Asia Pacific being the largest region, accounting for approximately 35% of the market share, and Latin America being the fastest-growing region, driven by increasing adoption of inhaler medicines and favorable policies. Key drivers for North America include high infrastructure maturity, significant investments in research and development, and a well-established ecosystem. In Europe, key drivers include a large patient population, stringent policies and regulations, and a strong focus on demographics and ecosystem maturity.

In Asia Pacific, key drivers include a large and growing patient population, increasing adoption of inhaler medicines, and significant investments in healthcare infrastructure. Latin America is driven by increasing adoption, favorable policies, and a growing ecosystem. The Middle East & Africa region is driven by a growing patient population, increasing adoption, and significant investments in healthcare infrastructure, contributing to the regional forecast.

Competitive Landscape

The Inhaler Medicine market is moderately consolidated, driven by a mix of global players and local companies. The Inhaler Medicine competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players tend to focus on premium pricing and innovation, while local companies often prioritize affordability and regional expansion.

Companies in the Inhaler Medicine market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and commoditization. To stay competitive, companies must leverage technology, service models, channel strength, customization, and cost advantages. The following companies have adopted distinct strategies:

GSK: regional expansion

AstraZeneca: innovation pipeline

Chiesi: premium pricing

Boehringer Ingelheim: local manufacturing

Novartis: OEM tie-ups

Teva: vertical integration

Key Inhaler Medicine Companies7 items

GSK

AstraZeneca

Chiesi

Boehringer Ingelheim

Novartis

Teva

Organon

Market Ecosystem

The Inhaler Medicine ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, suppliers, integrators, channels, and end users. Value is created and captured through the development, manufacturing, and distribution of inhaler devices and medications, with each segment influencing the overall efficiency and effectiveness of the ecosystem. A comprehensive value chain analysis is essential to understanding the intricacies of the Inhaler Medicine ecosystem.

Raw material/component suppliers — provide essential components

OEMs / manufacturers — design and produce inhaler devices

Technology providers — develop innovative inhaler technologies

Distributors / channel partners — facilitate device and medication distribution

Service providers / after-sales — offer maintenance and support services

Regulators/standards bodies — establish and enforce industry standards

End users / buyers — drive demand for inhaler devices and medications

In the Inhaler Medicine ecosystem, control points are largely influenced by regulators and standards bodies, as they dictate the approval and adoption of new devices and medications. Dependency risks arise from input constraints, such as the availability of raw materials, and standards approvals, which can impact the production and distribution of inhaler devices. Furthermore, switching costs and partnerships between manufacturers and distributors can affect the overall efficiency of the ecosystem, while interoperability requirements may vary by region, leading to differences in the ecosystem's structure and dynamics across diverse areas.

Recent Industry Insights

The Inhaler Medicine industry trends have witnessed significant developments over the last 12-18 months. Notably, there have been several strategic partnerships, such as collaborations between pharmaceutical companies and technology firms, aimed at enhancing inhaler design and improving patient outcomes. Additionally, the industry has seen a few mergers and acquisitions, with companies seeking to expand their product portfolios and strengthen their market presence.

Furthermore, there have been several product launches, including the introduction of new inhaler devices with advanced features such as dose tracking and connectivity. Regulatory changes, such as updated guidelines for inhaler testing and approval, have also had an impact on the industry. A shift in consumer trends towards more user-friendly and environmentally sustainable inhaler options has been observed, driving innovation in the sector. Moreover, companies have secured funding rounds to support research and development of new inhaler technologies, underscoring the industry's growth potential.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Inhaler Medicine market outlook. The market exhibits moderate attractiveness due to increasing prevalence of respiratory diseases and growing demand for inhaler devices. The competitive intensity is high, with key players investing heavily in research and development to improve product efficacy and patient compliance.

The long-term outlook for the Inhaler Medicine market is promising, driven by advancements in innovation landscape and rising awareness about respiratory health. However, the demand–supply balance may be affected by key risk factors such as regulatory changes and patent expirations. Decision-makers should consider these factors when navigating the Inhaler Medicine market outlook and developing strategies for growth and sustainability.

11 items

1. Executive Summary

2. Inhaler Medicine Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Inhaler Medicine Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Inhaler Medicine Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. COPD

6.1.2. Asthma

6.1.3. Other

6.2. Global Inhaler Medicine Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Short-acting Medicines

6.2.2. Long-acting Medicines

6.3. Global Inhaler Medicine Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Inhaler Medicine Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Inhaler Medicine Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Inhaler Medicine Market Competition by Key Manufacturers

8.1. Global Inhaler Medicine Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Inhaler Medicine: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. GSK

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. AstraZeneca

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Chiesi

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Boehringer Ingelheim

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Novartis

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Teva

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Organon

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Inhaler Medicine Market

Figure 4: Global Inhaler Medicine Market: Drivers

Figure 5: Global Inhaler Medicine Market: Challenges

Figure 6: Global Inhaler Medicine Market: Trends

Figure 7: Global Inhaler Medicine Market: Opportunity

Figure 8: Global Inhaler Medicine Market: Restraint

Figure 9: Global Inhaler Medicine Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Inhaler Medicine Market Value (USD Million) By Region

Figure 15: Global Inhaler Medicine Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Inhaler Medicine Market Value (USD Million) By Region

Figure 23: Global Inhaler Medicine Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

67 items

Table 1: Market Segmentation Analysis

Table 2: Global Inhaler Medicine Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Inhaler Medicine Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Inhaler Medicine Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Inhaler Medicine Market Value (USD Million) By Region

Table 10: Global Inhaler Medicine Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Inhaler Medicine Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Inhaler Medicine Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Inhaler Medicine Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: GSK Basic Information And Sales Area

Table 31: GSK. Products Portfolio

Table 32: AstraZeneca Basic Information And Sales Area

Table 33: AstraZeneca. Products Portfolio

Table 34: Chiesi Basic Information And Sales Area

Table 35: Chiesi. Products Portfolio

Table 36: Boehringer Ingelheim Basic Information And Sales Area

Table 37: Boehringer Ingelheim. Products Portfolio

Table 38: Novartis Basic Information And Sales Area

Table 39: Novartis. Products Portfolio

Table 40: Teva Basic Information And Sales Area

Table 41: Teva. Products Portfolio

Table 42: Organon Basic Information And Sales Area

Table 43: Organon. Products Portfolio

Table 44: Global Market Value (USD Million) (2025-2032) By Application

Table 45: Global Market Share (%) By Application (2032)

Table 46: Global Market Value (USD Million) (2025-2032) By Types

Table 47: Global Market Share (%) By Types (2032)

Table 48: Global Inhaler Medicine Market Value (USD Million) By Region

Table 49: Global Inhaler Medicine Market Share (%) By Region (2025-2032)

Table 50: North America Market Value (USD Million) (2025-2032) By Country

Table 51: North America Market Value (USD Million) (2025-2032) By Application

Table 52: North America Market Value (USD Million) (2025-2032) By Types

Table 53: Europe Market Value (USD Million) (2025-2032) By Country

Table 54: Europe Market Value (USD Million) (2025-2032) By Application

Table 55: Europe Market Value (USD Million) (2025-2032) By Types

Table 56: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 57: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 59: South America Market Value (USD Million) (2025-2032) By Country

Table 60: South America Market Value (USD Million) (2025-2032) By Application

Table 61: South America Market Value (USD Million) (2025-2032) By Types

Table 62: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 63: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 65: Research Programs/Design For This Report

Table 66: Key Data Information From Secondary Sources

Table 67: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Inhaler Medicine Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	8.50 million
Revenue forecast in 2033	14.82 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	GSK; AstraZeneca; Chiesi; Boehringer Ingelheim; Novartis; Teva; Organon
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options